Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03662243 · ClinicalTrials.gov registry record

Treatment for Reading and Writing Deficits Following Acquired Brain Injury

A clinical trial, sponsored by Quality Living.

Completed
Registry status
2
Enrollment target

NCT03662243: Completed study, sponsored by Quality Living.

NCT03662243 is a clinical trial that has completed, run by Quality Living. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03662243 has completed, sponsored by Quality Living.

COMPLETED
Registry status
2 participants
Enrollment target

Study Summary

Many people with acquired brain injuries have deficits in reading decoding, reading comprehension, and written expression. Alexia is a phenomenon in which a person who previously could read has trouble doing so after having sustained a brain injury; likewise, agraphia is an acquired writing problem affecting one or more aspects of written communication. Alexia and agraphia sometimes co-occur with one another and/or with other language challenges, but they can also occur as isolated phenomena. Methods to treat alexia and agraphia often focus on single intervention techniques that address aspects of reading or writing in isolation-such as matching written and spoken letters or letter sounds, performing choral reading, tracing letters, etc. Existing research suggests that the effectiveness of these techniques is limited. However, when used in combination, such techniques may promote improved reading and written communication skills. As such, the purpose of this research is to determine the extent to which a multicomponent intervention program improves the reading and writing capabilities of people with acquired alexia and/or agraphia.

Primary Outcome

Subtest raw sores range from 0 to 32,with higher scores indicating better performance.

Interventions

  • BEHAVIORAL Multicomponent reading and writing treatment

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2018-08-30
Est. Completion 2020-09-15
Quality Living

4 total trials

What the finished NCT03662243 record still lists

NCT03662243 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Multicomponent reading and writing treatment is the first listed.

NCT03662243 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03662243 about?

NCT03662243 is a clinical study titled "Treatment for Reading and Writing Deficits Following Acquired Brain Injury". Many people with acquired brain injuries have deficits in reading decoding, reading comprehension, and written expression. Alexia is a phenomenon in which a person who previously could read has trouble doing so after having sustained a brain injury; likewise, agraphia is an acquired writing problem ...

What is the current status of trial NCT03662243?

This trial is currently completed. The enrollment target is 2 participants. The study started on 2018-08-30. Estimated completion is 2020-09-15.

What interventions are being tested in trial NCT03662243?

The interventions under investigation include: Multicomponent reading and writing treatment (BEHAVIORAL).

Who is sponsoring clinical trial NCT03662243?

This trial is sponsored by Quality Living, which has 4 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03662243, the US trial registry maintained by the National Library of Medicine. NCT03662243 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.